A Brief History in Cardiac Regeneration, and How the Extra Cellular Matrix May Turn the Tide

Atze van der Pol* and Carlijn V. C. Bouten

Eindhoven University of Technology, Department of Biomedical Engineering, Eindhoven, Netherlands

Tissue homeostasis is perturbed by stressful events, which can lead to organ dysfunction and failure. This is particularly true for the heart, where injury resulting from myocardial infarction or ischemic heart disease can result in a cascading event ultimately ending with the loss of functional myocardial tissue and heart failure. To help reverse this loss of healthy contractile tissue, researchers have spent decades in the hopes of characterizing a cell source capable of regenerating the injured heart. Unfortunately, these strategies have proven to be ineffective. With the goal of truly understanding cardiac regeneration, researchers have focused on the innate regenerative abilities of zebrafish and neonatal mammals. This has led to the realization that although cells play an important role in the repair of the diseased myocardium, inducing cardiac regeneration may instead lie in the composition of the extra cellular milieu, specifically the extra cellular matrix. In this review we will briefly summarize the current knowledge regarding cell sources used for cardiac regenerative approaches, since these have been extensively reviewed elsewhere. More importantly, by revisiting innate cardiac regeneration observed in zebrafish and neonatal mammals, we will stress the importance the extra cellular matrix has on reactivating this potential in the adult myocardium. Finally, we will address how we can harness the ability of the extra cellular matrix to guide cardiac repair thereby setting the stage of next generation regenerative strategies.

Keywords: cardiac regeneration, extra cellular matrix, stem cells, heart failure, developmental biology

INTRODUCTION

Heart failure (HF) is a leading public and clinical health problem of the 21st century with a prevalence of more than 23 million worldwide (1, 2). HF as a result of myocardial infarction (MI) and ischemic heart disease remains the most prominent health challenge of the developed world, with a 5 year survival rate of <50% (3). The pathophysiology of HF resulting from MI or ischemic heart disease is characterized by the acute or gradual loss of functional cardiomyocytes. The remaining cardiomyocytes ineffectively attempt to compensate for the loss of myocardium, initiating a cascade of biological processes which eventually lead to cardiac remodeling. Cardiac remodeling induces scar tissue formation, ventricular wall thickening, and eventually diminished cardiac muscle functionality. Current clinical therapeutic interventions allow to slow down the progression of post-infarction HF, but are unable to cure the loss of functional tissue, i.e., to replace myocardial scaring with functional contractile tissue. Such therapies include several forms of drug treatments (e.g., ACE inhibitors), lifestyle modifications, surgery and ultimately heart transplantation. Cardiac transplantation is to date the only curative option for end-stage heart
failure but due to the low number of organ donors and the side effects of immunosuppressive drugs, only a few thousand patients a year have access to a transplantation program. Making it increasingly urgent to devise novel approaches to treat these patients.

Over the past decade multiple advances have been made in our understanding of myocardial cell homeostasis, stem cell biology, and matrix biology facilitating the identification of several novel therapeutic strategies directed at healing the myocardium. Many regenerative strategies have focused on cell-based approaches, however the heart is more than just the sum of its parts. The cellular composition of the heart plays a large role in the onset/development of post-infarction HF, however an equally great part is played by the micro-environment of the cell (i.e., the ECM and the cell-matrix interactions) when looking at cardiac repair, remodeling, and injury. The presence of aberrant ECM, as is the case in post-infarction HF development/progression, can reduce or even block the effectiveness of cell-based therapies to repair the heart (4). Interestingly, clues have emerged that the ECM is involved in development and in tissue repair in various organisms (e.g., zebrafish), not just for the heart but also within other organs (5). This begs the question: what would happen if the innate cardiac cells in the injured myocardium are provided with a healthy matrix/micro-environment?

With an eye to the future, in this review we will briefly revisit the shortcomings of stem cell-based approaches and stress how understanding the innate ability of the ECM in zebrafish and neonatal mammals for cardiac regeneration may offer alternative approaches to advance curative therapeutic strategies for patients suffering from post-infarction HF.

**STEM-CELL BASED CARDIAC REGENERATION: A FUTILE HISTORY**

With the goal of being a one-shot solution to cardiac injury, researchers have attempted to identify a cell source capable of inducing cardiac tissue regeneration. This has led to the investigation of several putative stem-cell based therapies to either stimulate the endogenous cells or deliver exogenous stem cells to trigger cardiac regeneration in the preclinical animal setting and in clinical trials; including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), bone marrow-derived stem cells, and most recently cardiac stem cells (CSCs). Despite these immense efforts, only limited and temporary clinical benefits have been observed, and whatever effects have been largely explained by paracrine cues associated with aiding the reduction of the inflammatory response (6, 7).

Of all the stem cell-based approaches, bone marrow-derived stem cells have been the most extensively studied for their cardiac regenerative potential, and over the years a multitude of experimental and clinical studies have been performed. A recent meta-analysis of 43 randomized controlled clinical trials, with 2,635 patients, focused on exploring the results at 6 months, 1 year, 3 years, and 5 years following the exogenously administration of bone marrow stem cells in patients with acute myocardial infarction (8). The authors observed a minor, but significant improvement, in left ventricular ejection fraction (LVEF) at 1 year, when compared to the control groups. However, at the 3 and 5 year follow-up, there was no significant difference in LVEF between the cell therapy and control groups, suggesting a severe decline in cardiac function in treatment group. A similar trend was observed when the authors looked at infarct sizes. These temporary improvements observed with bone marrow-derived stem cells have also been made in the few studies that have administered human ESC in to HF patients, although the long term effects of this approach have yet to be explored (9, 10). One important pitfall within these studies utilizing bone marrow-derived stem cells or ESC is that none of these studies demonstrated correct integration of the cells within the injured myocardium. Like ESCs, iPSCs derived cardiomyocytes have been recently shown to possess the ability to contract, form gap junctions, and even express the receptors essential for hormonal regulation of the myocardium (11, 12). These cells have shown great promise in the experimental setting, however the risk of vector and/or pluripotency-associated teratoma induced immunogenicity has to be circumvented prior to the initiation of cell based human clinical trials (13). Additionally, as with the previous studies utilizing bone marrow-derived stem cells or ESC, it is highly unlikely that a pure cell-based strategy with iPSC will result in long term beneficially effects. This may lie in the fact that these cells are unable to survive in the injured myocardium micro-environment, and therefore long term beneficial effects may not be achievable with this approach.

The final, and most controversial target for cardiac stem cell-based regeneration are the endogenous CSC. The notion that the adult heart is not just a post-mitotic organ, but has a limited extend for self-renewal, came about from advances in radiocarbon dating (14). In addition several populations of CSC residing within the heart have been identified (4). It has been suggested that these CSCs are responsible for reconstituting a finite basal rate of cardiomyocyte loss, although a direct link between cardiomyocyte renewal and these CSCs has yet to be demonstrated (15). These early findings have pointed to possibilities of utilizing resident cardiac progenitor populations for cardiac regeneration, however recent findings have brought into question the existence of these CPC in the heart (16–18). It has become evident that the renewal of cardiomyocytes in the adult myocardium is mainly due to the proliferation of existing cardiomyocytes rather than by the differentiation of putative progenitor cells (16, 19). Additionally, several recent lineage tracing studies have found that c-kit cardiac progenitors capacity to differentiate into cardiomyocytes is only 0.002–0.035% (16). These recent observations bring severe doubt into the regenerative potential of CPC, making it clear that alternative approaches must be developed to achieve post-injury myocardial regeneration.

Based on these significant advances in stem cell biology, it has become apparent that although healthy stem cells with cardiomyogenic potential are important, they can by themselves not lead to the long term goal of repairing the injured myocardium. This is in large part due to the toxic effects the pathological micro-environment, specifically the diseased extra-cellular matrix (ECM), has on the regenerative
The mammalian heart has always been considered to be a post-mitotic organ without the capacity for self-renewal, where growth is achieved through cellular hypertrophy. Recently, however, several studies have identified that cardiomyocytes retain the capacity to proliferate to a limited extend in the postnatal heart of both mice, rats, pigs, and humans (14, 27–31). Research has also shown that the immature mammalian heart possess a greater regenerative potential than previously expected (14). Given the similarities between the adult zebrafish heart and the immature mammalian heart, Porrello et al induced cardiac damage, by resection of 15% of the ventricular apex, in 1-day-old neonatal mice (32, 33). Surprisingly, the apex was progressively regenerated, with full restoration of the resected myocardium within 21 days. This regenerative ability of the immature heart was lost once the mice became over seven days old. More recently, similar observations have been made in rats and pigs (29, 30). And even more fascinating several case reports have demonstrated a similar phenomenon in newborn human babies (34, 35). This suggests that at birth mammals retain a surprising cardiac regenerative ability, which is lost upon maturation. Understanding which intrinsic mechanisms are involved in neonatal mammalian cardiac regeneration has triggered a new field of research into characterizing this innate ability for cardiac repair, which may facilitate the identification of novel strategies for cardiac regeneration in the failing heart.

THE ECM IN CARDIAC REGENERATION: AN EMERGING HISTORY

The regenerative potential of zebrafish and of neonatal mammals is truly astonishing, and to this day still baffles the scientific community. In spite of this, recent advances in stem cell biology, molecular biology, and matrix biology have started to unravel this mystery and suggested a key role in cardiac regeneration is played by the constitution of the ECM (36, 37). One of the earliest studies to focus on the regenerative potential of the ECM, utilized decellularized zebrafish cardiac ECM and injected this ECM solution into a murine MI model (38). Surprisingly, this study found that zebrafish ECM was able to stimulate the repair of the diseased myocardium, by inducing cardiomyocyte proliferation, reducing infarct size, and thereby overall improving cardiac function. In an in vitro setting the zebrafish ECM was also found to have a positive effect on the proliferation of human cardiac progenitor cells. A similar observation was made utilizing fetal, neonatal and adult cardiac ECM from rats to assess the potential of this ECM for neonatal rat cardiomyocyte expansion in vitro (39). The authors found that fetal cardiac ECM improved the overall adhesion and resulted in a 4-fold increase in cardiomyocytes population, when compared to adult cardiac ECM. Analogous observations were made when utilizing fetal pig ECM in a murine MI model (40). Since cross-species strategies might limit the translational potential of this approach, as is the case with injecting zebrafish ECM within a murine MI model, a recent study has also assessed the regenerative potential of the neonatal murine ECM (41). In this study decellularized neonatal cardiac ECM from
mice was injected into a murine MI model. As with the early zebrafish studies it was observed that the neonatal ECM limited scar tissue formation in the left ventricle and promoted revascularization of the injured region. These observations suggest that the fetal/neonatal cardiac ECM has a profound impact on the regenerative potential of the myocardium, and might explain the regenerative capacity of the fetal/neonatal mammalian heart, albeit the role of the individual and combined ECM components has not yet been fully analyzed (14, 27–30). The ECM is a complex mix of various components and to further explore this approach for clinical application it is essential to understand the exact composition of the ECM and which components are responsible for the regenerative potential of the fetal/neonatal ECM.

Advances in RNA sequencing and proteomics analysis, have enabled researchers to begin to unravel the components of the cardiac ECM which are responsible for its regenerative potential (41–49) (**Table 1**). Utilizing zebrafish as a model for cardiac regeneration, several studies have characterized the composition of the regenerative zebrafish ECM (42, 43). These studies identified that the regenerating cardiac zebrafish ECM had an abundance in hyaluronic acid (HA), an unbranched glycosaminoglycan polymer widely distributed in the ECM. Interestingly, depending on the molecular weight of HA, it has different biological activities such as promoting angiogenesis, inhibiting cell adhesion, and suppressing fibrotic tissue formation (56). The pathway for the production of HA is highly enriched within injured zebrafish myocardium, suggesting an important role in the regeneration of the heart (43). Indeed, when HA production is inhibited, this results in a total block of cardiac regeneration in zebrafish (43). A similar study also identified the ECM component fibronectin being highly expressed in the regenerating zebrafish heart (48). Interestingly, when inducing a loss-of-function mutation of fibronectin in zebrafish, this significantly reduced their cardiac regenerative abilities (48).

As with the discovery of HA and fibronectin, recent work has also identified agrin, a member of the proteoglycan family, to be highly enriched in the ECM of fetal/neonatal murine hearts and not in the hearts of adult mice (46). Interestingly, purified recombinant agrin had a pro-proliferative effect on cardiomyocytes cultured in vitro. When mice exposed to MI were administered with an intramyocardial injection of agrin, a significant improvement in cardiac function was observed with a reduction in overall myocardia injury. To further explore the cardiac regenerative potential of agrin, recombinant agrin was administered to porcine ischemia-reperfusion (IR) model (45). As in the murine setting, agrin improved cardiac function and reduced cardiac remodeling following IR injury. Although this field of research is still in its infancy, these observations do suggest that an increased understanding of the ECM may prove invaluable to unlock the intrinsic regenerative potential of the adult myocardial tissue.

**DISCUSSION**

**ECM Driven Cardiac Regeneration: Where Do We Go From Here?**

Although significant advances have been made in the field of cardiovascular medicine, diseases such as myocardial infarction (MI) and ischemic heart disease, ultimately resulting in heart failure, remain amongst the leading causes of fatalities in the developed world. The mortality of these cardiovascular diseases is in no small part due to the irreversible loss of vessels and cardiomyocytes resulting in a decreased cardiac functionality. Current therapeutic strategies are aimed at alleviating the symptoms rather than repairing the loss of functioning cardiac

---

**TABLE 1** | Differential Expression of extracellular matrix (ECM) components in regenerative vs. non-regenerative hearts in different species.

| ECM component | Regenerative | Non-regenerative | Studies demonstrating ECM component involvement in cardiac regeneration |
|---------------|--------------|-----------------|---------------------------------------------------------------------|
| Agrin         | ↑ (50)       | ↓ (39)          | Recombinant Agrin promotes cardiac regeneration (45, 46)             |
| Collagen-I    | ↑ (42)       | ↓ (39)          | Fibronectin is important for zebrafish cardiac regeneration (48)     |
| Collagen-IV   | ↑ (42)       | ↓ (39)          | Hyaluronic acid inhibition blocks zebrafish cardiac regeneration (43, 49) |
| Collagen-V    | ↑ (42)       | ↓ (39)          | Periostin involved in neonatal, and not adult, cardiac regeneration (47, 53–55) |
| Collagen-VI   | ↑ (42)       | ↓ (39)          |                                                                     |
| Fibrin        | ↑ (42)       | ↓ (39)          |                                                                     |
| Fibronectin   | ↑ (50)       | ↑ (36)          |                                                                     |
| Hyaluronic acid | ↑ (42)    | ↑ (51)          |                                                                     |
| Laminin       | ↓ (39)       | ↓ (36)          |                                                                     |
| Periostin     | ↑ (50)       | ↑ (39)          |                                                                     |
| Perlecian     | ↑ (39)       | ↓ (39)          |                                                                     |
| Thrombospondin | ↑ (37)     | ↓ (37)          |                                                                     |
| Versican      | ↑ (37)       | ↓ (37)          |                                                                     |

↑, denotes high expression of selected ECM component. ↓, denotes low expression of selected ECM component.
Thus, researchers have turned to the field of regenerative medicine to identify novel strategies aimed at regenerating and/or repairing the number of functioning cardiac muscle cells within the failing heart.

Based on the current state-of-the-art, it is becoming increasingly evident that the utilization of stem-cell based approaches to achieve regeneration of the adult mammalian myocardium may not be the silver bullet scientists originally hoped for. Over the past decades several breakthroughs have been made in stem-cell biology that have enabled researchers to investigate numerous cell sources for cardiac regenerative purposes, and although some of these studies have demonstrated improvements in cardiac function in the translational setting, actual regeneration of the myocardium has yet to be demonstrated. This suggest that many of the cell sources for cardiac regeneration may hold a paracrine effect on the myocardium post-injury. Therefore, it has become evident that novel approaches have to be explored to attain true regeneration of the damaged myocardium.

This is where unraveling the regenerative capacities of the zebrafish and/or neonatal mammalian heart may come in to play. Specifically when looking at the ECM, since several studies have demonstrated that the ECM of zebrafish and neonatal mammalian hearts possess an innate regenerative potential when applied to injured adult hearts. The undisputable potential the ECM has to regenerate the damaged myocardium as also lead to the development of an injectable hydrogel derived from porcine decellularized myocardial ECM (VentricGel), which has recently also been tested in the clinical setting (57). This study tested the efficacy and safety of the treatment, nevertheless patients did demonstrate an overall improvement following VentriGel treatment. It must be note that this therapeutic strategy, although highly innovative, does possess the drawback of being derived from porcine hearts and one can therefore not exclude any interspecies complications that may arise from this. A more suitable approach would be to develop a therapeutic strategy, a hydrogel-based one, which is synthetic and encompasses only the ECM components required to attain innate cardiac regeneration.

**FIGURE 1 | Advancement in ECM based cardiac regenerative research.** To advance the field of cardiac regeneration it is essential to take advantage of the innate regenerative capacity of the fetal mammalian heart. “Developmental ECM selection” will require: (1) the utilization of advancements in “-omics” techniques, such as RNA sequencing and proteomics, to identify key ECM components present in the fetal/developing heart, (2) developmental ECM components will need to be screened in vitro for their capacity to influence cardiac regeneration, a key component of which is the induction of cardiomyocyte proliferation, and (3) the delivery of candidate developmental ECM components will have to be determined, either by means of a naturally produced ECM hydrogel, a synthetically produced ECM hydrogel, or by direct administration of the recombinant ECM component (TOP panel, from left to right). Having selected the most suitable ECM component for cardiac regeneration and the delivery system, these will have to be tested for their in vivo capacity to induce cardiac regeneration. The first step will revolve around animal model experiments, either in a rodent model (as depicted) or in a large mammal model (i.e., pig) for heart failure. Here the developed hydrogel harboring the ECM of interest or the recombinant ECM solution will be administered to the animals to determine their efficacy in inducing cardiac regeneration and improving overall cardiac function. The final step, and most crucial, will be to translated this ECM based therapeutic strategy into the clinic.
regeneration. This idea is further strengthened by recent studies which characterized HA and agrin, components of the ECM, as possessing strong cardiac regenerative potentials. Therefore, future studies should aim at improving our knowledge of the fetal/neonatal ECM and thereby unraveling the regenerative potential of this ECM to be harnessed for the development of novel therapeutic strategies of HF patients (Figure 1).

To push the field of cardiac regenerative medicine forward, several hurdles will have to be overcome before we can develop therapeutic strategies to be implemented in a clinical setting. Firstly, we must understand the "why" neonatal mammalian or zebrafish ECM is able to induce adult cardiac regeneration. To this end advances in omics-based approaches, including proteomics and RNA-sequencing, will enable scientists to fully characterize the composition of these early ECMs and identify which components are no longer present in the adult myocardium (58). Next, we must determine "how" these candidate ECM components are able to induce repair/regeneration of the injured myocardium (in vitro and in vivo). Finally, and the most crucial step will be the development of these ECM components into a synthetic hydrogel to facilitate the move into clinical application. Advances in the field of synthetic biomaterial have demonstrated the potential for the generation of such synthetic ECM hydrogels (59, 60). Although still in their infancy, the move toward a synthetic ECM hydrogel will facilitate the clinical usability of such a therapeutic strategy. A recent study has demonstrated the potential of this by developing a degradable elastin-like polypeptide hydrogel, which mimics the ECM (61). Intramyocardial injection of this hydrogel in a sheep model for myocardial infarction lead to a reduction in fibrosis, increased angiogenesis, improved cardiac function and cardiomyocyte integrity in the border zone of the infarcts (61). Taken together, these steps will not only help our understanding of cardiac regeneration as a whole, but will also lead to an improved outcome for patients suffering from HF.

ECM Driven Cardiac Regeneration: Limitations and Cavities

One of the greatest obstacles that has to be overcome is our current knowledge gap related to the demonstrated role the ECM, in particular the neonatal ECM, plays in cardiac regeneration (29, 30, 32–35). Understanding the composition of the neonatal ECM will give a great impulse in the field of cardiac regeneration. However, scientists working on studying the role of neonatal ECM components for regenerative purposes must keep in mind the various functions and effects ECM components have. A prime example of this was the discovery of periostin, an ECM-associated proteins, which like Agrin was found to be highly expressed in the neonatal mammalian heart and barely detectable in the adult heart (52). Periostin was found to induce cardiomyocyte cell cycle re- following MI, resulting in improved cardiac function (47, 53). However, in the adult murine heart knocking-out or overexpressing periostin was found to have no effect on cardiomyocyte proliferation (54). But, reducing the expression of periostin in cardiac fibroblasts did result in a reduction in adverse cardiac remodeling in a murine MI model (55). This demonstrates that not all fetal ECM components will have the same effect in the neonatal heart as in the adult heart, and scientists must be critical when unraveling the regenerative potential of the fetal/neonatal ECM.

AUTHOR CONTRIBUTIONS

AvdP and CB contributed to planning, writing, and critical reading of this manuscript. Both authors contributed to the article and approved the submitted version.

FUNDING

The authors gratefully acknowledge funding from the Ministry of Education, Culture and Science for the Gravitation Program 024.003.013 Materials Driven Regeneration.

ACKNOWLEDGMENTS

The authors thank Prof. Dr. Jonathan T. Butcher (Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA) for critical comments and suggestions on the manuscript.

REFERENCES

1. Roger VL. Epidemiology of heart failure. Circ Res. (2013) 113:646–59. doi: 10.1161/CIRCRESAHA.113.300268
2. Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. (1997) 337:1360–9. doi: 10.1056/NEJM199711063371906
3. Stewart S, Macintyre K, Hole DJ, Capewell S, McMurray JJV. More “malignant” than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. (2001) 3:315–22. doi: 10.1016/S1388-9842(00)00141-0
4. Mauretti A, Spaans S, Bax NAM, Sahlgren C, Bouter CVC. Cardiac progenitor cells and the interplay with their microenvironment. Stem Cells Int. (2017) 2017:7471582. doi: 10.1155/2017/7471582
5. Konttinen YT, Kaivosoja E, Stegaev V, Wagner HD, Levón J, Tiainen VM, et al. Extracellular matrix and tissue regeneration. In: Regenerative Medicine: From Protocol to Patient. Netherlands: Springer. p. 21–40. doi: 10.1007/978-90-481-9075-1_2
6. Laflamme MA, Chen KY, Naumova AV, Mushkeli V, Fugate JA, Dupras SK, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. (2007) 25:1015–24. doi: 10.1038/nbt1327
7. Awada HK, Hwang MP, Wang Y. Towards comprehensive cardiac repair and regeneration after myocardial infarction: aspects to consider and proteins to deliver. Biomaterials. (2016) 82:94–112. doi: 10.1016/j.biomaterials.2015.12.025
8. Lee SH, Hong JH, Cho KH, Noh JW, Cho HJ. Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis. Stem Cell Res Ther. (2016) 7:153. doi: 10.1186/s13287-016-0415-z
9. Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Cacciapuoti I, et al. Human embryonic stem cell-derived cardiac progenitors for severe
heart failure treatment: first clinical case report. Eur Heart J. (2015) 36:2011–7. doi: 10.1093/eurheartj/ehv189

10. Menasché P, Vanneau A, Hégéz A, Bel A, Cholley B, Parouchiev A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol. (2018) 71:429–38. doi: 10.1016/j.jacc.2017.11.047

11. Pfannkuche K, Liang H, Hannes T, Xi J, Fatima A, Nguemo F, et al. Cardiac myocytes derived from murine reprogrammed fibroblasts: intact hormonal regulation, cardiac ion channel expression and development of contractility. Cell Physiol Biochem. (2009) 24:73–86. doi: 10.1159/000227815

12. Gai H, Leung ELH, Costantino PD, Aguila JR, Nguyen DM, Fink LM, et al. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol Int. (2009) 33:1184–93. doi: 10.1016/j.cellbi.2009.08.008

13. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction with induced pluripotent stem cells induced by human stemness factors. Circulation. (2009) 120:408–16. doi: 10.1161/CIRCULATIONAHA.109.865154

14. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heide E, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. (2009) 324:98–102. doi: 10.1126/science.1164680

15. Malliaras K, Marbán E. Cardiac cell therapy: where we been, where we are, and where we should be headed. Br Med Bull. (2011) 98:161–85. doi: 10.1093/bmb/ldr018

16. Cai C-L, Molkentin JD. The elusive progenitor cell in cardiac regeneration. Circ Res. (2010) 120:400–6. doi: 10.1161/CIRCRESAHA.116.309710

17. He L, Nguyen NB, Ardehali R, Zhou B. Heart regeneration. Circulation. (2009) 119:1288–96. doi: 10.1161/CIRCULATIONAHA.109.865154

18. Kajstura J, Urbanek K, Perl S, Hosoda T, Zheng H, Ogórek B, et al. Transplantation of human embryonic stem cell–derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. Eur Heart J. (2011) 32:2011–7. doi: 10.1093/eurheartj/ehv189

19. Vagnozzi RJ, Molkentin JD, Houser SR. New myocyte formation in the adult heart. J Clin Invest. (2012) 122:275–91. doi: 10.1172/JCI59648

20. Kretschmar K, Post Y, Bannister-Heloüet M, Mattiotti A, Drost J, Basak O, et al. Profiling proliferative cells and their progeny in damaged murine hearts. Proc Natl Acad Sci U S A. (2011) 108:112245–54. doi: 10.1073/pnas.1015829115

21. Vagnozzi RJ, Molkentin JD. The elusive progenitor cell in cardiac regeneration. Circ Res. (2018) 123:159–76. doi: 10.1161/CIRCRESAHA.118.311208

22. Barianni PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. (2010) 5:121–43. doi: 10.2217/rme.09.74

23. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. (2002) 298:2188–90. doi: 10.1126/science.1077857

24. Raya A, Roth CM, Büscher D, Kawakami Y, Itoh T, Rayma RM, et al. Activation of Notch signaling pathway precedes heart regeneration in zebrafish. Proc Natl Acad Sci U S A. (2003) 100:11889–95. doi: 10.1073/pnas.183042100

25. Silva AC, Pereira C, Fonseca ACRG, Pinto-do-Ó P, Nascimento DS. Bearing my heart: the role of extracellular matrix on cardiac development, homeostasis, and injury response. Front Cell Dev Biol. (2021) 9:18705. doi: 10.3389/fcell.2020.621644

26. Chen WCW, Wang Z, Missinato MA, Park DW, Long DW, Liu HJ, et al. Decellularized zebrafish cardiac extracellular matrix induces mammalian heart regeneration. Sci Adv. (2016) 2:1600844. doi: 10.1126/sciadv.1600844

27. Williams C, Quinn KP, Georgakoudi I, Black LD. Young developmental age cardiac extracellular matrix promotes the expansion of neonatal cardiomyocytes in vitro. Acta Biomater. (2014) 10:1994–2004. doi: 10.1016/j.actbio.2013.08.037

28. Wang X, Senapati S, Akinbote A, Gnanasambandam B, Park PS, Senyo SE. Microenvironment stiffness requires decellularized cardiac extracellular matrix to promote heart regeneration in the neonatal mouse heart. Acta Biomater. (2020) 113:380–92. doi: 10.1016/j.actbio.2020.06.032

29. Wang Z, Long DW, Huang Y, Chen WCW, Kim K, Wang Y. Decellularized neonatal cardiac extracellular matrix prevents widespread ventricular remodeling in adult mammals after myocardial infarction. Acta Biomater. (2019) 87:140–51. doi: 10.1016/j.actbio.2019.01.062

30. Garcia-Puig A, Mosquera JL, Jiménez-Delgado S, García-Pastor C, Rorba J, Navajas D, et al. Proteomics analysis of extracellular matrix remodeling during zebrafish heart regeneration. Mol Cell Proteomics. (2019) 18:1745–55. doi: 10.1074/mcp.RA118.001193

31. Missinato MA, Tobita K, Romano N, Carroll JA, Tsang M. Extracellular component hyaluronic acid and its receptor Hmmr are required for epicardial EMT during heart regeneration. Cardiovasc Res. (2015) 107:487–98. doi: 10.1093/ cvr/cv0190

32. Lien C-L, Schebesta M, Makino S, Weber GJ, Keating MT. Gene expression analysis of zebrafish heart regeneration. PLoS Biol. (2006) 4:e260. doi: 10.1371/journal.pbio.0040260

33. Baehr A, Umanovsky KB, Bassat E, Jurisch V, Klett K, Bozoglu T, et al. Agrin promotes coordinated therapeutic processes leading to improved cardiac repair in pigs. Circulation. (2020) 142:868–81. doi: 10.1161/CIRCULATIONAHA.119.051116

34. Basat E, Mutlak YE, Genzelinakh A, Shadrin IY, Baruch Umansky K, Yifa O, et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. (2017) 547:179–84. doi: 10.1038/nature22978

35. Kühn B, Del Monte F, Hajar RJ, Chang YS, Lebeche D, Arab S, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med. (2007) 13:962–9. doi: 10.1038/ nm1619

36. Wang J, Karra R, Dickson AL, Poss KD. Fibronectin is deposited by injury-activated epicardial cells and is necessary for zebrafish heart regeneration. Dev Biol. (2013) 382:427–35. doi: 10.1016/j.ydbio.2013.08.012
49. Yoon SJ, Fang YH, Lim CH, Kim BS, Son HS, Park Y, et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. J Biomed Mater Res Part B Appl Biomater. (2009) 91B:163–71. doi: 10.1002/jbm.b.31386

50. Sánchez-Iranzo H, Galardi-Castilla M, Sanz-Morejón A, González-Rosa JM, Costa R, Ernst A, et al. Transient fibrosis resolves via fibroblast inactivation in the regenerating zebrafish heart. Proc Natl Acad Sci U S A. (2018) 115:4188–93. doi: 10.1073/pnas.1716713115

51. Fenderson BA, Stamenkovic I, Aruffo A. Localization of hyaluronan in mouse embryos during implantation, gastrulation and organogenesis. Differentiation. (1993) 54:85–98. doi: 10.1111/j.1432-0436.1993.tb01591.x

52. Snider P, Hinton RB, Moreno-Rodriguez RA, Wang J, Rogers R, Lindsley A, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res. (2008) 102:752–60. doi: 10.1161/CIRCRESAHA.107.159517

53. Chen Z, Xie J, Hao H, Lin H, Wang L, Zhang Y, et al. Ablation of periostin inhibits post-infarction myocardial regeneration in neonatal mice mediated by the phosphatidylinositol 3 kinase/glycogen synthase kinase 3β/cyclin D1 signalling pathway. Cardiovasc Res. (2017) 113:620–32. doi: 10.1093/cvr/cvx001

54. Lorts A, Schwanekamp JA, Elrod JW, Sargent MA, Molkentin JD. Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. Circ Res. (2009) 104:e1–7. doi: 10.1161/CIRCRESAHA.108.188649

55. Kaur H, Takefuji M, Ngai CY, Carvalho J, Bayer J, Wietelmann A, et al. Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice. Circ Res. (2016) 118:1906–17. doi: 10.1161/CIRCRESAHA.116.308643

56. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. (2006) 85:699–715. doi: 10.1016/j.ejcb.2006.05.009

57. Traverse JH, Henry TD, Dib N, Patel AN, Pepine C, Schaer GL, et al. First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients. JACC Basic Transl Sci. (2019) 4:659–69. doi: 10.1016/j.jacbts.2019.07.012

58. Method of the Year 2020: Spatially Resolved Transcriptomics. Available online at: https://www.nature.com/collections/dlf6ggefc/ (accessed March 8, 2021)

59. Spaans S, Fransen PP, Lippel BD, De Bont DFA, Keizer HM, Bax N, et al. Supramolecular surface functionalization: via catechols for the improvement of cell-material interactions. Biomater Sci. (2017) 5:1541–8. doi: 10.1039/C7BM00407A

60. Hasan A, Khattab A, Islam MA, Hweij KA, Zeitoony J, Waters R, et al. Injectable hydrogels for cardiac tissue repair after myocardial infarction. Adv Sci. (2015) 2:1500122. doi: 10.1002/advs.201500122

61. Contessotto P, Orbanic D, Da Costa M, Jin C, Owens P, Chantepie S, et al. Elastin-like recombinamers-based hydrogel modulates post-ischemic remodeling in a non-transmural myocardial infarction in sheep. Sci Transl Med. (2021) 13:eaz5380. doi: 10.1126/scitranslmed.aaz5380

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 van der Pol and Bouten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.